Michael McKeown

Michael McKeown is a highly skilled professional working at the intersection of small molecules and biology to combat severe human diseases.

With a Ph.D. in Chemical Biology from Harvard University and a B.S. in Chemistry/Biochemistry from UC San Diego, Michael has a strong educational background to support his expertise.

He currently serves as the Principal Scientist Pharmacology at Kronos Bio, Inc., showcasing his leadership and capabilities in pharmaceutical research.

Michael's previous roles include being a Principal Scientist in Chemical Biology at Cygnal Therapeutics, Senior Scientist at Constellation Pharmaceuticals, Investigator II at Novartis Institutes for BioMedical Research (NIBR), and held senior positions at Syros Pharmaceuticals.

His experience also includes research roles during his time as a Graduate Student at Dana Farber Cancer Institute and Harvard University, as well as a Research Assistant at UC San Diego.

Michael emphasizes the need for multidisciplinary teams adept in computational biology, cancer biology, and chemistry for successful drug discovery beyond the traditional approaches.

His work revolves around addressing the challenges following the depletion of 'low hanging fruit' in drug discovery, underlining the necessity for diverse scientific communication and collaboration.

Michael McKeown continues to drive advancements in the pharmaceutical industry through his research, leadership, and expertise.